Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform

Area of Science:

• Oncology
• Computational Biology
• Pharmacology

Background:

• Glioma is an aggressive brain tumor with limited therapeutic options.
• Novel drug discovery is crucial for improving patient outcomes.
• Existing treatment strategies require innovative approaches.

Purpose of the Study:

• To predict novel glioma therapies using the Computational Analysis of Novel Drug Opportunities (CANDO) platform.
• To identify potential drug candidates by analyzing drug-protein interactions and proteomic-scale compound behavior.
• To validate the CANDO platform's efficacy in discovering glioma-associated drugs.

Main Methods:

• Utilized the CANDO platform to compute interaction scores between drug libraries and proteins, generating "interaction signatures."
• Ranked compounds based on signature similarity to approved drugs and degree of consensus.
• Benchmarked CANDO performance by measuring the recovery of known glioma drugs against random controls.
• Identified novel predictions through literature-based analysis of highly ranked compounds.

Main Results:

• CANDO demonstrated improved accuracy in identifying glioma-associated drugs compared to random controls.
• The study predicted 23 potential glioma treatments, including vitamin D, taxanes, vinca alkaloids, and folic acid.
• Key predicted targets included Vitamin D3 receptor, acetylcholinesterase, and dihydrofolate reductase.

Conclusions:

• The CANDO platform's multitarget, multiscale framework is effective for identifying glioma drug candidates.
• These findings inform new strategies for improving glioma treatment through computational drug discovery.
• The study highlights the potential of repurposed and novel compounds for glioma therapy.